Drug Discovery

Viatris, Kindeva launch Breyna to treat asthma and COPD patients

Viatris and Kindeva Drug Delivery have launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol to treat certain asthma and chronic obstructive pulmonary disease (COPD) patients.

NMPA accepts Overland ADCT BioPharma’s BLA for ZYNLONTA

The China National Medical Products Administration (NMPA) has accepted and granted priority review to Overland ADCT BioPharma’s biologics license application (BLA) for ZYNLONTA (loncastuximab tesirine-lpyl).

Sandoz launches action plan to improve access to biosimilar medicines

Generic and biosimilar medicines provider Sandoz has introduced a global action plan to provide patients with quick access to biologic medicines.

Fresenius Kabi introduces Vasopressin Injection, USP, in US

A global health care company Fresenius Kabi has announced the availability of Vasopressin injection, USP, in the US for treating adults with vasodilatory shock.

Charles River Laboratories, Curigin partner on gene therapy

Charles River Laboratories International has teamed up with Korean biotechnology company Curigin for producing oncolytic ribonucleic acid interference (RNAi) gene therapy.

EdgeCap Partners buys majority stake in Comac Medical

Private equity and growth capital firm EdgeCap Partners has acquired a majority stake in Bulgarian clinical research solutions organisation (CRO) Comac Medical.

Athenex files proceedings under Chapter 11 of US Bankruptcy Code

Biopharmaceutical company Athenex and some of its subsidiaries voluntarily have filed Chapter 11 proceedings of the US Bankruptcy Code.

SGS picks 60% stake in Nutrasource

Swiss company SGS has purchased a majority stake in Nutrasource Pharmaceutical and Nutraceutical Services as well as its subsidiaries (Nutrasource).

Sandoz, Just – Evotec Biologics tie up to develop multiple biosimilars

Sandoz and Evotec’s Seattle-based subsidiary, Just - Evotec Biologics have reached a multi-year, long-term tech alliance to develop and manufacture multiple biosimilars.